Evaluation of the Laboratory Response Network and Testing Access During the First 10 Weeks of the Mpox Response, United States, May 17-July 31, 2022.

IF 3 4区医学 Q2 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH Public Health Reports Pub Date : 2024-08-27 DOI:10.1177/00333549241269497

Katharine L Thomas, Tricia A Aden, Patricia A Blevins, Amanda J Raziano, Tyler Wolford, Margaret A Honein, Julie M Villanueva

{"title":"Evaluation of the Laboratory Response Network and Testing Access During the First 10 Weeks of the Mpox Response, United States, May 17-July 31, 2022.","authors":"Katharine L Thomas, Tricia A Aden, Patricia A Blevins, Amanda J Raziano, Tyler Wolford, Margaret A Honein, Julie M Villanueva","doi":"10.1177/00333549241269497","DOIUrl":null,"url":null,"abstract":"Objectives: The Laboratory Response Network (LRN) consists of US and international laboratories that respond to public health emergencies, such as biothreats. We used a qualitative approach to assess the successes and challenges of the LRN during the initial 10 weeks of the 2022 mpox outbreak (May 17-July 31, 2022).Methods: We conducted 9 unstructured interviews, which included 3 interviews with subject matter experts from the Centers for Disease Control and Prevention (CDC) and 6 interviews with state and local public health laboratories and epidemiologists and Association of Public Health Laboratories (APHL) staff. We asked guiding questions on investments in preparedness, successes, and challenges during the initial mpox response and asked for suggestions to improve future LRN responses to infectious disease outbreaks. We also reviewed data from 2 contemporaneous APHL surveys conducted in June and July 2022 in 84 LRN public health laboratories.Results: Notable successes included availability of an assay that had received clearance from the US Food and Drug Administration (FDA) for testing orthopoxviruses (non-variola Orthopoxvirus [NVO] assay) and a trained workforce; strong relationships among FDA, CDC, and the LRN; and strong communications between LRN laboratories and CDC. Challenges included variability among LRN laboratories in self-reported testing capacity, barriers to accessing the NVO assay for health care providers, and gaps in LRN function during surges of testing needs.Conclusions: The LRN system plays an essential role in the response to emerging infectious disease outbreaks in the United States. Lessons learned from the LRN's initial response to the mpox outbreak can help guide improvements to better position the LRN for future responses, including continued engagement with health care providers, commercial laboratories, and laboratories in health care settings.","PeriodicalId":20793,"journal":{"name":"Public Health Reports","volume":" ","pages":"333549241269497"},"PeriodicalIF":3.0000,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11569720/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Public Health Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/00333549241269497","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: The Laboratory Response Network (LRN) consists of US and international laboratories that respond to public health emergencies, such as biothreats. We used a qualitative approach to assess the successes and challenges of the LRN during the initial 10 weeks of the 2022 mpox outbreak (May 17-July 31, 2022).

Methods: We conducted 9 unstructured interviews, which included 3 interviews with subject matter experts from the Centers for Disease Control and Prevention (CDC) and 6 interviews with state and local public health laboratories and epidemiologists and Association of Public Health Laboratories (APHL) staff. We asked guiding questions on investments in preparedness, successes, and challenges during the initial mpox response and asked for suggestions to improve future LRN responses to infectious disease outbreaks. We also reviewed data from 2 contemporaneous APHL surveys conducted in June and July 2022 in 84 LRN public health laboratories.

Results: Notable successes included availability of an assay that had received clearance from the US Food and Drug Administration (FDA) for testing orthopoxviruses (non-variola Orthopoxvirus [NVO] assay) and a trained workforce; strong relationships among FDA, CDC, and the LRN; and strong communications between LRN laboratories and CDC. Challenges included variability among LRN laboratories in self-reported testing capacity, barriers to accessing the NVO assay for health care providers, and gaps in LRN function during surges of testing needs.

Conclusions: The LRN system plays an essential role in the response to emerging infectious disease outbreaks in the United States. Lessons learned from the LRN's initial response to the mpox outbreak can help guide improvements to better position the LRN for future responses, including continued engagement with health care providers, commercial laboratories, and laboratories in health care settings.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

2022 年 5 月 17 日至 7 月 31 日，美国，麻疹疫情应对前 10 周实验室应对网络和检测通道评估》（Evaluation of Laboratory Response Network and Testing Access during the First 10 Weeks of Mpox Response, United States, May 17-July 31, 2022）。

目标：实验室响应网络（LRN）由应对生物威胁等公共卫生突发事件的美国和国际实验室组成。我们采用定性方法评估了实验室响应网络在 2022 年麻风腮疫情爆发的最初 10 周（2022 年 5 月 17 日至 7 月 31 日）所取得的成功和面临的挑战：我们进行了 9 次非结构化访谈，其中包括 3 次与疾病控制和预防中心（CDC）的主题专家的访谈，6 次与州和地方公共卫生实验室、流行病学家以及公共卫生实验室协会（APHL）工作人员的访谈。我们提出了一些指导性问题，内容涉及对准备工作的投资、成功经验以及在最初应对麻疹疫情过程中遇到的挑战，并就改进未来 LRN 应对传染病疫情的措施征求了建议。我们还审查了 2022 年 6 月和 7 月在 84 个 LRN 公共卫生实验室进行的 APHL 两次同期调查的数据：显著的成功包括：拥有美国食品药品管理局（FDA）批准的用于检测矫形痘病毒的检测方法（non-variola Orthopoxvirus [NVO]检测方法）和训练有素的员工队伍；FDA、CDC 和 LRN 之间关系密切；LRN 实验室和 CDC 之间沟通顺畅。面临的挑战包括 LRN 实验室在自我报告检测能力方面的差异、医疗服务提供者在获得 NVO 检测方面的障碍，以及在检测需求激增时 LRN 功能的缺口：LRN 系统在应对美国新发传染病疫情中发挥着重要作用。从 LRN 对麻风腮疫情的初步反应中吸取的经验教训有助于指导改进工作，使 LRN 能够更好地应对未来的反应，包括继续与医疗服务提供者、商业实验室和医疗机构中的实验室合作。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Public Health Reports 医学-公共卫生、环境卫生与职业卫生

CiteScore

5.00

自引率

6.10%

发文量

164

审稿时长

6-12 weeks

期刊介绍： Public Health Reports is the official journal of the Office of the U.S. Surgeon General and the U.S. Public Health Service and has been published since 1878. It is published bimonthly, plus supplement issues, through an official agreement with the Association of Schools and Programs of Public Health. The journal is peer-reviewed and publishes original research and commentaries in the areas of public health practice and methodology, original research, public health law, and public health schools and teaching. Issues contain regular commentaries by the U.S. Surgeon General and executives of the U.S. Department of Health and Human Services and the Office of the Assistant Secretary of Health. The journal focuses upon such topics as tobacco control, teenage violence, occupational disease and injury, immunization, drug policy, lead screening, health disparities, and many other key and emerging public health issues. In addition to the six regular issues, PHR produces supplemental issues approximately 2-5 times per year which focus on specific topics that are of particular interest to our readership. The journal''s contributors are on the front line of public health and they present their work in a readable and accessible format.